Breast cancer
Oncology· 20 reviewed drugs· 41331 cited findings behind them
What the regulatory reviews cover
Regulatory review documents for several drugs related to breast cancer are available in this library. These include Enhertu, Perjeta, Kisqali, Ibrance, Abraxane, Trodelvy, Taxotere, Faslodex, Tukysa, VERZENIO, Retevmo, Kadcyla, Truqap, Orserdu, Xeloda, Halaven, Phesgo, Herceptin, Datroway, and Zolsketil pegylated liposomal.
The reported results vary by drug and trial. For example, Perjeta showed a PFS improvement of 38, while Ibrance demonstrated a median progression-free survival of 24.8 with IBRANCE plus Letrozole compared to 14.5 with Placebo plus Letrozole. VERZENIO reported a median progression-free survival (PFS) of 16.4 with abemaciclib + fulvestrant versus 9.3 with placebo + fulvestrant. Halaven showed a Median OS of 399 compared to 324 for the comparator. It is important to note that these figures are from different studies and are not directly comparable head-to-head.
The drugs — one cited result each
| Enhertu Daiichi Sankyo Company, Limited | Objective response rate (ORR): 60.3 Daiichi Sankyo Company, Limited — Enhertu FDA Review (BLA761, p.18 |
| Perjeta Roche Holding AG | PFS improvement: 38 Roche Holding AG — Perjeta EMA EPAR public assessment report, p.3 |
| Kisqali Novartis AG | Hazard ratio (95% CI) for iDFS: 0.749 (0.628, 0.892) Novartis AG — Kisqali FDA Review (NDA/BLA 209092, 2026), p.31 |
| Ibrance Pfizer Inc. | Median progression-free survival (IBRANCE plus Letrozole): 24.8 PFIZER — Ibrance FDA Review (NDA/BLA 207103, 2019), p.25 |
| Abraxane Bristol-Myers Squibb Company | median overall survival (Abraxane/gemcitabine): 8.5 months Abraxane FDA Review (NDA/BLA 021660, 2019), p.52 |
| Trodelvy Gilead Sciences, Inc. | Median PFS: 5.5 Gilead Sciences, Inc. — Trodelvy FDA Review (BLA761115, ORIG, p.65 |
| Taxotere Sanofi | overall response rate: 37.9% SANOFI AVENTIS US — Taxotere FDA Review (NDA/BLA 020449, 202, p.52 |
| Faslodex AstraZeneca PLC | median OS (months): 22.8 ASTRAZENECA — Faslodex FDA Review (NDA/BLA 021344, 2019), p.128 |
| Tukysa Pfizer Inc. | OS Hazard Ratio: 0.68 Pfizer Inc. — Tukysa FDA Review, p.24 |
| VERZENIO Eli Lilly and Company | median progression-free survival (PFS) (abemaciclib + fulvestrant): 16.4 Eli Lilly and Company — Verzenio FDA Review (NDA208716, ORIG, p.27 |
| Retevmo Eli Lilly and Company | 1566 cited findings on the drug page → |
| Kadcyla Roche Holding AG | Median Progression-free survival: 14.2 Roche Holding AG — Kadcyla EMA EPAR public assessment report, p.74 |
| Truqap AstraZeneca PLC | 1303 cited findings on the drug page → |
| Orserdu Stemline B V | 1039 cited findings on the drug page → |
| Xeloda Cheplapharm | 742 cited findings on the drug page → |
| Halaven Eisai Co., Ltd. | Median OS (Halaven): 399 Halaven EMA EPAR public assessment report, p.41 |
| Phesgo Roche Holding AG | 487 cited findings on the drug page → |
| Herceptin Roche Holding AG | 452 cited findings on the drug page → |
| Datroway Daiichi Sankyo Company, Limited | 129 cited findings on the drug page → |
| Zolsketil pegylated liposomal Accord S L U | 68 cited findings on the drug page → |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Oncology research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.